Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 9/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4016564 | 0.85 | PTPN11 (0.35) | PTPN11NPC1POLBMAPTRAB9A | |
| SCHEMBL4015930 | 0.84 | PAX8 (0.50) | PAX8BRD4NPC1POLBMAPT | |
| SCHEMBL4013687 | 0.80 | LCK (0.42) | PTPN11NPC1POLBMAPTRAB9A | |
| SCHEMBL31342724 | 0.74 | BRD4 (0.43) | PAX8BRD4MAPTCREBBPAAK1 | |
| SCHEMBL4014579 | 0.74 | BRD4 (0.43) | PAX8BRD4MAPTCREBBPAAK1 | |
| SCHEMBL18896595 | 0.74 | GPBAR1 (0.40) | BRD4AAK1 | |
| SCHEMBL27539398 | 0.71 | ALDH1A1 (0.42) | PAX8BRD4CREBBPAAK1ALDH1A1 | |
| SCHEMBL15156318 | 0.69 | ALDH1A1 (0.46) | PAX8BRD4MAPTAAK1ALDH1A1 | |
| SCHEMBL12324089 | 0.68 | PAX8 (0.51) | PAX8NPC1MAPTRAB9AALDH1A1 | |
| SCHEMBL31433093 | 0.68 | TUBB4A (0.41) | PAX8BRD4NPC1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632851-B2 | Benzo[1,2,5]oxadiazoles and benzol[1,2,5]thiadiazoles useful as histopathological staining agents, imaging agents and biomarkers | NOVARTIS AG (CH) | 2009-12-15 | — | — | US | disclosed |
| EP-1613610-B1 | BENZO 1,2,5 OXADIAZOLES AND BENZO 1,2,5 THIADIAZOLES USEFUL AS HISTOPATHOLOGICAL STAINING AGENTS, IMAGING AGENTS AND BIOMARKERS | NOVARTIS AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| US-20060093551-A1 | Benzo[1,2,5]oxadiazoles and benzol[1,2,5]thiadiazoles useful as histopathological staining agents, imaging agents and biomarkers | NOVARTIS AG (CH) | 2006-05-04 | — | — | US | disclosed |
| EP-1613610-A1 | BENZO 1,2,5 OXADIAZOLES AND BENZO 1,2,5 THIADIAZOLES USEFUL AS HISTOPATHOLOGICAL STAINING AGENTS, IMAGING AGENTS AND BIOMARKERS | Novartis AG (CH) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087684-A1 | BENZO[1,2,5]OXADIAZOLES AND BENZO [1,2,5]THIADIAZOLES USEFUL AS HISTOPATHOLOGICAL STAINING AGENTS, IMAGING AGENTS AND BIOMARKERS | NOVARTIS AG (CH) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060093551-A1 | Benzo[1,2,5]oxadiazoles and benzol[1,2,5]thiadiazoles useful as histopathological staining agents, imaging agents and biomarkers | H1-3, MKI67, H1-5 | PAX8 1249/4885BRD4 149/4885PTPN11 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.